CRISPR Therapeutics Stock: Bull vs. Bear
CRISPR Therapeutics' (NASDAQ: CRSP) gene-editing technologies use the Cas9 enzyme as a mechanism for cutting a targeted piece out of DNA -- with the aim of treating serious illnesses and conditions. Its therapies might just change the world. On the other hand, the company has been posting substantial losses as it moves toward bringing treatments to market, and its performance outlook is uncertain.
Should investors put their money behind this promising biotech stock, or is this a case where the fruits of a revolutionary concept will never be realized? Read on to see why two Motley Fool contributors come down on different sides of the bull-versus-bear debate on CRISPR Therapeutics.